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A simultaneous study of the metabolism of apolipoprotein B and
albumin in nephrotic patients.
Background. The nephrotic syndrome is characterized by pro-
teinuria, hypoalbuminemia and hyperlipidemia. Despite intensive
research it is not clear at present what the causal links are between
these pathological findings.
Methods. Stable isotope labeled amino acid tracer kinetic
analysis was used to simultaneously investigate the metabolism of
four apolipoprotein B-containing lipoproteins (VLDL1, VLDL2,
IDL and LDL) and albumin in seven patients with nephrotic
syndrome and marked hypercholesterolemia, in two additional
nephrotic patients with concomitant renal failure and mixed
hyperlipidemia, and in a matched group of normolipidemic
controls.
Results. Increased concentrations of VLDL2, IDL and LDL
were due to (a) impaired VLDL2 and IDL delipidation, (b)
reduced LDL catabolism, and (c) a trend towards an increased
rate of total apolipoprotein B production. The rate of fractional
albumin elimination was three times higher in patients than in
controls and the rate of albumin synthesis was increased by 45%.
No correlations were detectable between rates of apolipoprotein
B production and the rate of albumin synthesis.
Conclusions. The results of this study suggest that hyperlipid-
emia in nephrotic syndrome is predominantly the result of delayed
lipoprotein delipidation and catabolism. There is no evidence that
it is driven by a general increase of the rate of hepatic protein
synthesis.
Hyperlipidemia with increased cholesterol and triglycer-
ide levels in plasma is a typical feature of the nephrotic
syndrome [1]. Usually, low density lipoprotein (LDL) con-
centrations are increased well above the normal range, but
very low density (VLDL) may also be increased, particu-
larly in cases of marked hypoalbuminemia or in the pres-
ence of concomitant renal failure [2]. In contrast, high
density lipoproteins (HDL) have been reported to be either
normal or decreased [3]. In general, VLDL is secreted by
hepatocytes as a lipoprotein consisting mainly of triglycer-
ides and the apolipoprotein B-100. By stepwise delipidation
and lipid exchange VLDL is transformed in the plasma
compartment into cholesteryl ester rich intermediate den-
sity lipoproteins (IDL) and eventually into LDL. While the
lipid moiety of these lipoproteins is extensively modified
and remodeled in this process, the apo B-100 molecule is
preserved and stays with a lipoprotein particle from its
nascent state until it is finally eliminated from the circula-
tion either by binding to the LDL receptor or through
receptor-independent mechanisms. For the general popu-
lation it is now well established that increased LDL con-
centrations are correlated with an increased risk for coro-
nary heart disease. The increased levels of apo B containing
lipoproteins, particularly in the density range of IDL and
LDL, are a major reason for the accelerated atherosclerosis
observed in patients with nephrotic syndrome [4, 5].
The disturbance of apolipoprotein B metabolism in the
nephrotic syndrome is thought to be caused by increased
secretion of apo B containing lipoproteins either alone [6,
7] or in combination with impaired lipoprotein clearance
from the plasma [8–11]. Studies in humans [6–12], exper-
imental animals [13–17], and in in vitro systems [18–20]
have produced evidence for both pathogenic principles.
However, it is still a matter of controversy whether in-
creased synthesis or reduced catabolism are the leading
cause of hyperlipidemia in nephrotic patients. One com-
mon hypothesis suggests that hypoalbuminemia due to
urinary protein losses results in increased hepatic albumin
synthesis, which in turn leads to a generalized increase in
hepatic protein synthesis including apolipoprotein B pro-
duction [14, 21]. Alternatively, it is assumed that apo B
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production is enhanced by a reduction of plasma oncotic
pressure due to low plasma albumin concentrations [18]. As
a result, one would expect to find either rates of albumin
synthesis or albumin plasma levels to be correlated with
rates of apolipoprotein B production in hyperlipidemic
nephrotic patients.
Until recently the metabolism of apo B-containing li-
poproteins and of albumin could not be investigated at the
same time in the same individual. Therefore, virtually all
studies published thus far are confined to the kinetic
analysis of either lipoprotein or albumin metabolism and
sought to draw conclusions with regard to the other com-
ponent by monitoring surrogate metabolic parameters such
as plasma concentrations [8, 22, 23]. By the combined use
of stable isotope labeled amino acid tracers, sensitive mass
spectrometric analysis and multicompartmental kinetic
modeling, it has become possible to study the metabolism
of two or even more proteins simultaneously in one subject
[24–26].
Here we report the results from a metabolic study in nine
nephrotic patients where deuterated leucine was used as a
tracer for endogenous labeling of newly synthesized pro-
teins in order to investigate the putative links between
albumin and apolipoprotein B metabolism.
METHODS
Subjects
Seven patients participating in this study were recruited
from out-patient clinics of the nephrology units of three
different hospitals. They suffered from nephrotic syndrome
for one to eight years and fulfilled the following selection
criteria: (a) proteinuria . 5.0 g/day, (b) serum creatinine ,
1.3 mg/dl (115 mmol/liter), and (c) plasma cholesterol .
250 mg/dl (6.5 mmol/liter). Details of their histological
diagnoses, serum creatinine concentrations and urinary
protein losses are listed in Table 1. Biometrical data
together with lipoprotein profiles are given in Table 2. Two
other patients with nephrotic syndrome (HS and KD)
who did not fulfill the above selection criteria due to
moderate renal insufficiency were also included in the
present study. However, results from their metabolic trials
were recorded separately and were not pooled with those of
the study group. Patients received diuretics (furosemide
plus amiloride or hydrochlorothiazide, all except MC) and
Table 1. Nephrological diagnosis and non-lipid parameters of patients with nephrotic syndrome
Name
Creatinine
mg/dl
Urinary protein Urinary albumin
Nephrological diagnosis
based on histology
Duration of disease
yearsg/24 h
WM 1.2 16.3 14.0 membranous glomerulonephritis 4
KF 1.2 16.0 14.0 membranous glomerulonephritis 2
JO 0.9 11.4 10.1 membranous glomerulonephritis 2
HA 1.1 9.6 9.6 membranous glomerulonephritis 1
MC 0.8 12.0 9.3 membranous glomerulonephritis 5
EA 0.4 —a —a focal segmental glomerulosclerosis 6
ED 0.7 7.3 4.6 focal segmental glomerulosclerosis 8
Mean 6 SD 0.9 6 0.3 12.1 6 3.5 9.5 6 3.3
HS 2.7 5.4 5.4 chronic glomerulonephritis (no histology) 4
KD 2.4 4.1 3.9 focal segmental glomerulosclerosis 1
a Not available from the time of turnover study
Table 2. Lipoproteins and biometric data of patients with nephrotic syndrome
Name Sex
Age
years
Body wt
kg
Height
m
Albumin
g/dl
Total
chol. Triglycerides
VLDL-
chol.
LDL-
chol.a
HDL-
chol.
mg/dl
WM m 50 90 1.76 2.8 292 440 77 182 33
KF m 56 102 1.78 2.6 282 202 38 182 62
JO m 62 70 1.67 2.8 413 127 25 317 72
HA m 52 73 1.59 2.9 500 182 36 373 90
MC m 32 76 1.80 2.7 292 163 32 210 49
EA f 21 65 1.66 1.7 365 105 21 302 42
ED f 36 56 1.68 2.5 259 137 27 187 46
Mean 6 SD 44 6 15 76 6 15 1.71 6 0.08 2.6 6 0.4 343 6 88 194 6 114 37 6 19 250 6 79 56 6 20
Neph. vs. Cont. NS NS NS P , 0.001 P , 0.005 P , 0.020 P , 0.020 P , 0.007 NS
HC m 62 90 1.80 4.1 248 419 75 146 28
KD m 45 93 1.81 4.7 263 384 81 149 32
a Abbreviations are: chol., cholesterol, Neph. vs. Cont., nephrotics versus controls; LDL, low density lipoprotein; VLDL, very low density lipoprotein;
HDL, high density lipoprotein. “LDL” is determined by standard laboratory procedures in line with the Lipid Clinics Research protocol (for details see
[24]). It comprises the LDL- and IDL-fractions (Sf 0-20) prepared by cumulative gradient ultracentrifugation.
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angiotensin-converting-enzyme inhibitors (WM, KD, JO).
None of them was on immunosuppressive therapy and lipid
lowering drugs had been withdrawn for more than one
month prior to metabolic studies. A control group of nine
normolipidemic subjects was selected from laboratory staff
and medical students. Lipoprotein profiles and biometrical
data are presented in Table 3. Body mass indices (kg/m2) in
patients and in controls were not significantly different
(26.0 6 4.2 and 23.3 6 3.6 kg/m2, respectively; P 5 0.183).
Throughout the study, patients and controls were asked to
continue their normal diets. Three patients and five con-
trols prepared seven-day weighed food intake protocols
that were analyzed by a dedicated computer program
(Prodi; Nutriscience, Karlsruhe, Germany).
All subjects participating in this study gave informed
consent. The study met the requirements of the Ethics
Committees of the Klinikum Grosshadern in Munich, the
Carl-Thiem-Klinik in Cottbus, the Leicester General Hos-
pital in Leicester and the Royal Infirmary in Glasgow.
Turnover protocol
The protocol employed has been described in detail
elsewhere [24]. Subjects were fasted for 12 hours overnight
and at 8 a.m. the tracer amino acid, d3-leucine (Cambridge
Isotopes, Woburn, MA, USA), was given either as an
intravenous bolus injection (6.0 mg/kg body wt; subjects:
WM, JO, HS, KD, BG, BJ, WS, JD, GH) or as a primed
constant infusion (that is, a bolus of 0.6 mg/kg followed by
0.6 mg/kg/hr for 10 hr; subjects: KF, HA, MC, EA, ED, CE,
MM, RB, CS). Both methods of tracer administration have
been tested previously and found to provide identical
metabolic parameters [24, 25]. Plasma samples (10 ml
blood collected in EDTA) were collected for apolipopro-
tein B, albumin and plasma free leucine analysis immedi-
ately before tracer administration, at multiple time points
throughout the first 12 hours of the study, and thereafter,
daily in the fasting state for 12 days. A light meal was
offered 10 hours after tracer injection.
Lipoprotein isolation and preparation of apo B
VLDL1 (Sf 60 to 400), VLDL2 (Sf 20 to 60), IDL (Sf 12
to 20) and LDL (Sf 0 to 12) were prepared from 2 ml
plasma by cumulative gradient ultracentrifugation as pre-
viously described [24]. Briefly, 2 ml plasma were adjusted to
a density of d 5 1.118 g/ml by addition of solid NaCl and
built into a discontinuous six-step salt gradient ranging
from d 5 1.0988 to 1.0588 g/ml. After the following
centrifugational runs at 23°C in a Beckman SW40 rotor,
lipoprotein preparations were collected from the surface of
the gradient: VLDL1 (1.0 ml, replaced by 1.0 ml of d 5
1.0588 g/ml solution), 39,000 rpm, 1.63 hours; VLDL2 (0.5
ml), 18.500 rpm, 15.68 hours; IDL (0.5 ml), 39,000 rpm,
2.58 hours; and LDL (1.0 ml), 30,000 rpm, 21.17 hours.
Prior to delipidation LDL preparations were tested for
contaminations by lipoprotein(a), which when detectable
was removed quantitatively by affinity chromatography
using immobilized wheat germ agglutinine [27]. Apo B was
precipitated from lipoprotein fractions by the addition of
an equal volume of isopropanol, the resulting pellet was
delipidated with ethanol:ether (3:1), dried with ether and
hydrolyzed at 110°C for 20 hours in the presence of 0.5 to
1.0 ml 6 N HCl, which was subsequently removed by
evaporation in a vacuum concentrator centrifuge [24].
Lipids were determined by routine laboratory tests and
protein was measured by the Lowry method as previously
described. Apo B plasma pools were derived from the apo
B content that was calculated as the difference between
total and isopropanol-soluble protein, and an estimate of
the plasma volume (4% of the body wt). The apo B masses
of each of the lipoprotein fractions were corrected for
experimental losses by comparing the total cholesterol
recovered in the four fractions obtained by cumulative
gradient ultracentrifugation, with the non-HDL cholesterol
value determined in native plasma. The fractional leucine
content of apo B was taken as 0.1212 g/g [24]. Lp(a) was
Table 3. Lipoproteins and biometric data of normal controls
Name Sex
Age
years
Body wt
kg
Height
m
Albumin
g/dl
Total
chol. Triglycerides
VLDL-
chol.
LDL-
chol.a
HDL-
chol.
mg/dl
BG m 30 83 1.80 — 175 89 19 104 52
CE m 29 61 1.75 4.8 202 95 20 136 47
MM m 30 81 1.78 — 215 80 27 118 70
BJ m 33 60 1.70 — 232 96 15 161 42
RB m 48 106 1.86 4.7 194 99 22 130 56
CS m 29 75 1.81 5.2 155 122 23 78 54
WS m 43 83 1.87 5.0 219 103 19 142 58
JD f 46 60 1.72 4.2 175 60 12 115 48
GH f 26 57 1.68 5.2 220 40 9 131 80
Mean 6 SD 35 6 8 74 6 16 1.78 6 0.07 4.9 6 0.4 199 6 26 87 6 24 18 6 6 124 6 24 56 6 12
Abbreviations are given in Table 2.
a See footnote a of Table 2
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quantified as Lp(a) total mass by an ELISA technique
(Immuno GmbH, Heidelberg, Germany).
Albumin preparation
Albumin was prepared from plasma by affinity chroma-
tography as described by Travis and Pannell [28]. EDTA-
plasma was diluted 1:10 with 0.05 M Tris, 0.10 M KCl (pH
7.0) and 3 ml were applied on a 2 ml column containing
Blue-Sepharose (Pharmacia, Upsala, Sweden). Non-bind-
ing plasma components were eluted with 3 3 2 ml 0.05 M
Tris, 0.10 M KCl (pH 7.0) and subsequently albumin was
desorbed with 0.05 M Tris, 1.50 M KCl (pH 7.0). It was
transferred into 0.10 M ammonium acetate (pH 7.0) by
passage over a NAP-5 column (Pharmacia, Upsala, Swe-
den), dried in a vacuum concentrator centrifuge and sub-
sequently hydrolyzed as described above. Immunoelectro-
pheresis of the desorbed protein fraction against anti-
human-plasma antiserum (Behring, Marburg, Germany)
showed a single band in the albumin position and no
additional protein contamination (data not shown). From
data in the literature a value of 0.1205 g/g for the leucine
content of albumin was adopted [29]. Albumin in native
plasma and in urine was determined by a nephelometric
routine laboratory procedure (Behring, Marburg, Germa-
ny).
Free amino acid preparation from plasma
Proteins were precipitated from 1 ml plasma by adding 1
ml trichloroacetic acid (10%) and amino acids prepared
from the supernatant by cation exchange chromatography
using 2 ml columns filled with Dowex AG-50W-X8 resin
(H1-form, 50 to 100 mesh; Biorad, Richmond, CA, USA).
The amino acids that bound to the resin were desorbed by
4 M NH4OH, which was subsequently removed by evapo-
ration in a vacuum concentrator [30]. The samples were
dissolved in a small volume of 1 M HCl, transferred into
microvials and dried again ready for derivatization.
Leucine tracer/tracee analysis by quadrupolar GC-MS
Amino acids derived from apo B, from albumin or from
plasma were transformed into tert-butyl-dimethyl-silyl
(TBDMS) derivatives by incubation with 50 ml of a freshly
prepared 1:1 mixture of N-methyl-N-(tert-butyl-dimethyl-
silyl)-trifluoro-acetamide (MTBSTFA; Fluka, Buchs, Swit-
zerland) and acetonitrile in crimped microvials at 80°C for
20 minutes. Enrichments were determined immediately by
gas chromatography mass spectrometry using a quadrupo-
lar GC-MS instrument (Trio 1000; Fisons, Manchester,
UK).
A detailed description of the method used for GC-MS
analysis has been published elsewhere [24]. The gas chro-
matograph was equipped with a DB1701 capillary column
(J&W, Folsom, CA, USA) operated at 110°C for one
minute after sample injection, followed by an increase of
temperature of 20°C/min up to 280°C. The mass spectro-
meter was used with electron impact ionization (EI1).
Leucine ion mass fragments were monitored and quantified
in the selective ion recording (SIR) mode at mass-to-charge
ratios (m/z) 277, m/z 276 and m/z 274. From these mea-
surements the specific isotopic enrichment (E) and the
leucine tracer/tracee ratio (Z) were calculated by the
following formulas [31]:
E 5 ~R 2 RN!/@~1 1 R! z ~1 1 RN!# (1)
where R is the m/z 277 to m/z 274 ratio for the enriched
sample and RN is the equivalent ratio for naturally occur-
ring leucine (RN 5 0.01697; N 5 10).
Z 5 E/~EI 2 E! (2)
where EI is the isotopic abundance of the infused tracer
that was determined to be 0.998.
Kinetic analysis and multicompartmental modeling
Typical examples for the time courses of leucine tracer/
tracee ratios measured in the four apo B-containing li-
poproteins and in albumin are shown in Figures 1 and 3.
They were analyzed using a computer program for simula-
tion, analysis and modeling (SAAM II, version 1.1.1;
SAAM Institute, Seattle, WA, USA). Kinetic analysis per-
formed on the basis of a metabolic model resulted in the
determination of transfer rate coefficients (ki,j) and masses
(Qi) for apolipoprotein B or albumin compartments. Val-
ues for ki,j describe the transfer of material from compart-
ment j to i as fraction of pool j per unit of time. Qi
quantifies the mass content of compartment i. Individual
transfer rate coefficients (ki,j) were summarized to provide
rates of protein secretion, transfer (where applicable) and
catabolism (Table 4). Kinetic parameters were usually
determined with a fractional SD (FSD) of less than 0.10. In
the few instances were FSD values were greater than 0.50
parameters were fixed at a calculated level. In all studies
simulation calculations were performed until convergence
between curves for observed and calculated tracer/tracee
ratios was reached and further iterations were aborted by
SAAM. Individual ki,j and Qi values and the appropriate
FSD values are given in Appendices I and II.
The model used for the quantitative analysis of apo B
metabolism as depicted in Figure 2A has been described in
detail elsewhere [24]. Its basic features are a four compart-
mental representation of free leucine kinetics (compart-
ments 1 to 4), a sequence of lipoprotein compartments
accounting for the stepwise delipidation of VLDL1 through
VLDL2 and IDL to LDL (compartments 6 to 7, 9 to 10, 12,
14) plus the three remnant compartments 8, 11 and 13 for
VLDL1, VLDL2 and IDL particles that are removed di-
rectly from plasma. Free leucine and the apo B-containing
compartments 6, 9, 12 and 14 in the VLDL1, VLDL2, IDL
and LDL density ranges are linked via a delay element
(compartment 5) that is set at 0.5 hours, accounting for the
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time required for apo B biosynthesis. Compartment 15
allows for some intra-/extravascular exchange of LDL that
is not observed for less dense lipoproteins. Requirements
for a priori system identifiability in accordance with physi-
ological considerations led to the introduction of the
following model constraints [24]: k2,1 5 k 1,2; k8,6 5 k11,9;
k0,8 5 k0,11; k7,6 5 k10,9; k13,10 5 k0,13; k0,10 5 k0,12; k14,15 5
2.5 * k15,14. Input of native leucine was represented in the
model by U1. To simulate the specific tracer enrichment in
the immediate precursor pool for apo B synthesis (com-
partment 5) and to fit observed tracer/tracee curves for
both plasma and lipoproteins, an additional tracee input
(U5) had to be allowed into compartment 5. U5 is an
additional unknown parameter that can be identified by
multicompartmental model analysis [24].
The model devised for analysis of albumin metabolism is
shown in Figure 2B. It consists of one plasma albumin
compartment and a second extravascular compartment
allowing for intra-/extravascular exchange. The plasma
compartment is linked via a delay element to the same four
compartmental model for free leucine that was used for
apo B kinetic analysis (Fig. 2A). In nephrotic patients the
calculated rate of albumin elimination from plasma (FER)
comprises both urinary albumin excretion and albumin
degradation by physiological mechanisms. The latter, which
is expressed as fractional catabolic rate (FCR), was calcu-
lated from the difference between total albumin elimina-
tion and urinary albumin loss.
Kinetic analysis by monoexponential curve fitting
In subjects who received the amino acid tracer as a
primed constant infusion the fractional elimination rate of
albumin (FER), was also determined by fitting a monoex-
ponential term to the observed data for albumin tracer
enrichment using the numerical mode of SAAM II. The
following formula was applied [32]:
y ~t! 5 Bmax p @1 2 e2FER p (t20.5)] (3)
where y (t) is the tracer/tracee ratio for albumin at time t
and Bmax is the plateau of the tracer/tracee ratio reached by
Fig. 1. Time courses of leucine tracer/tracee ratios from VLDL1 (M), VLDL2 (f), IDL (V) and LDL (l) in two patients with nephrotic syndrome (C,
KF, and D, JO) and two normal control subjects (A, MM, and B, WS). The ordinate represents leucine tracer/tracee ratios as calculated from GC-MS
measurements. Tracer was given as a bolus in patients MM and KF and as a primed constant infusion in WS and JO. Observed data are given as symbols
and calculated values are represented by continuous lines.
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VLDL1 10 hours after continuous tracer infusion. Since
VLDL1 is a rapidly turning over hepatic protein its Bmax
value can be taken as a measure of the tracer enrichment of
the hepatic precursor pool of protein synthesis [33].
Statistical analysis
Statistical analysis was performed using Minitab soft-
ware, version 11 (Minitab Inc., State College, PA, USA).
VLDL1
(Sf 60–400)
Synthesis
mg/kg/day
Pool
mg
Transfer
to VLDL2 Catabolism
pools/day
Patients
WM 19.9 574 2.02 1.10
KF 24.4 127 16.55 3.06
JO 9.8 70 8.55 1.16
HA 16.3 48 23.07 1.73
MC 25.0 109 6.62 10.80
EA 12.8 35 23.55 0.18
ED 14.5 125 4.49 2.03
Median 16.3 109 8.55 1.73
Range 9.8–25.0 35–574 2.0–23.6 0.2–10.8
HS 17.7 536 2.86 0.11
KD 26.8 464 3.38 1.99
Controls
BG 9.4 62 12.63 0.00
CE 19.4 53 8.66 13.77
MM 5.7 23 11.00 9.16
BJ 20.5 47 7.83 18.30
RB 25.4 114 10.94 12.77
CS 12.6 101 9.28 0.09
WS 17.1 59 10.43 13.86
JD 12.9 18 27.23 16.52
GH 18.7 24 24.50 20.41
Median 17.1 53 10.94 13.77
Range 5.7–25.4 18–114 7.8–27.2 0.0–20.4
P value
Neph. vs. Cont. 0.634 0.064 0.315 0.081
VLDL2
(Sf 20–60)
Synthesis
Flux from
VLDL1
Transfer
to IDL Catabolism
mg/kg/day
Pool
mg pools/day
Patients
WM 6.0 12.9 766 1.67 0.55
KF 1.7 20.6 689 2.34 0.96
JO 1.2 8.6 248 2.71 0.06
HA 1.6 15.2 460 2.65 0.01
MC 2.1 9.5 400 2.12 0.09
EA 9.0 12.8 211 6.65 0.05
ED 5.2 10.0 201 2.92 1.32
Median 2.1 12.8 400 2.65 0.09
Range 1.2–9.0 8.6–20.6 201–766 1.7–6.7 0.0–1.3
HS 6.0 17.0 691 1.76 1.23
KD 7.2 16.8 893 1.57 0.93
Controls
BG 2.0 9.4 111 7.95 0.62
CE 1.0 7.5 103 4.80 0.21
MM 1.8 3.1 126 3.00 0.14
BJ 0.5 6.1 131 3.03 0.01
RB 2.1 11.7 233 6.28 0.00
CS 3.3 12.5 163 4.51 2.74
WS 3.6 7.4 115 7.87 0.01
JD 2.4 8.0 86 4.95 2.28
GH 4.3 10.2 60 9.07 4.70
Median 2.1 8.0 115 4.95 0.21
Range 0.5–4.3 3.1–12.5 61–233 3.0–9.1 0.0–4.7
P value
Neph. vs. Cont. 0.525 0.023 0.002 0.007 0.711
IDL
(Sf 12–20)
Synthesis
Flux from
VLDL2
Transfer
to LDL Catabolism
mg/kg/day
Pool
mg pools/day
Patients
WM 0.6 14.2 605 1.28 0.92
KF 3.0 15.8 991 1.12 0.81
JO 0.6 9.6 783 0.56 0.35
HA 4.3 16.7 2245 0.65 0.03
MC 1.6 11.2 860 0.99 0.14
EA 2.8 21.6 794 1.62 0.37
ED 2.3 10.5 537 0.80 0.53
Median 2.3 14.2 794 0.99 0.37
Range 0.6–4.3 9.6–21.6 537–2245 0.6–1.6 0.0–0.9
HS 1.1 13.5 556 1.28 1.09
KD 3.0 15.1 1008 0.89 0.78
Controls
BG 0.5 10.6 337 2.15 0.59
CE 1.3 8.1 255 1.70 0.57
MM 6.9 4.7 534 1.74 0.02
BJ 1.0 6.6 328 1.40 0.00
RB 4.9 13.8 811 1.97 0.47
CS 2.3 9.8 209 2.42 1.93
WS 0.5 10.9 442 1.58 0.58
JD 2.4 7.1 289 1.96 0.03
GH 5.5 9.5 277 1.79 1.30
Median 2.3 9.5 328 1.79 0.57
Range 0.5–6.9 4.7–13.8 209–811 1.4–2.4 0.0–1.9
P value
Neph. vs. Cont. 0.916 0.013 0.004 0.002 0.832
LDL(Sf 0–12)
Synthesis
Flux from
IDL
Catabolism
pools/day
Total Apo B
production
mg/kg/daymg/kg/day
Pool
mg
Patients
WM 0.0 8.6 2660 0.29 26.5
KF 1.5 10.9 4310 0.29 30.6
JO 3.3 6.3 3366 0.20 14.8
HA 7.8 19.9 4239 0.48 30.0
MC 1.9 11.2 3090 0.32 30.6
EA 8.3 19.8 4339 0.41 32.9
ED 0.9 7.7 2282 0.21 22.9
Median 1.9 10.9 3368 0.29 30.0
Range 0.0–8.3 6.3–19.9 2282–4439 0.2–0.5 14.8–32.9
HS 1.2 7.9 2288 0.36 26.0
KD 0.2 9.6 3347 0.27 37.0
Controls
BG 1.9 8.7 1845 0.48 13.8
CE 0.5 7.1 1559 0.30 22.3
MM 3.8 11.5 1962 0.63 18.2
BJ 4.6 7.7 1730 0.42 26.6
RB 1.9 15.1 2756 0.65 34.2
CS 3.4 6.7 1337 0.57 21.6
WS 0.0 8.4 2577 0.27 21.3
JD 4.3 9.4 1649 0.50 22.0
GH 0.2 8.7 1306 0.39 28.6
Median 1.9 8.7 1730 0.48 22.0
Range 0.0–4.6 6.7–15.1 1306–2756 0.3–0.7 13.8–34.2
P value
Neph. vs. Cont. 0.832 0.597 0.003 0.034 0.153
Table 4. Metabolic parameters of apolipoprotein B, a constituent of VLDL1, VLDL2, IDL and LDL from patients with nephrotic syndrome and
from normal controls
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Fig. 2. Kinetic models of (A) free leucine and
apolipoprotein B metabolism and (B) free
leucine and albumin metabolism. Models were
used for computer-based kinetic analysis of
tracer/tracee data. k(i,j) denote kinetic rate
constants, Q(i) masses contained by individual
compartments and s(i) sampled lipoproteins or
albumin. Details are in the text and
Appendices.
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Results are shown as means and SDs or as medians and
ranges. Differences between nephrotic patients and con-
trols were evaluated by a non-parametric test (Kruskal-
Wallis). Correlations between metabolic parameters within
study groups were examined by Pearson’s correlation ma-
trix and regression analysis. For variables which were not
normally distributed as demonstrated by Minitab normality
plots the Spearman’s rank correlation coefficient was de-
termined prior to regression analysis. Differences and
correlations with P , 0.05 were considered as statistically
significant.
RESULTS
Seven patients, five males and two females, suffering
from nephrotic syndrome due to primary renal disease
participated in this study. Two subjects (HS and KD) who
had nephrosis as well as moderate renal failure were also
studied, but their results were considered separately and
are reported at the end of this section. Kidney biopsies
revealed membranous glomerulonephritis in five and focal
segmental glomerulosclerosis in three subjects (Table 1).
Proteinuria was in the range of 7.3 to 16.3 g/24 hours, and
about 85% of urinary protein was determined to be albu-
min. Plasma albumin levels were significantly reduced
(2.6 6 0.4 vs. 4.9 6 0.4 g/dl in controls). None of these
patients presented with signs of chronic renal failure such
as azotemia, hypertension or renal anemia. Renal disease
secondary to hypertension or diabetes was excluded in all
subjects. Serum creatinine concentrations were in the range
of 0.4 to 1.2 mg/dl. All patients displayed substantial
hyperlipidemia with total cholesterol concentrations of 259
to 500 mg/dl and triglycerides of 105 to 440 mg/dl. When
apolipoprotein B-containing lipoproteins were prepared
and analyzed separately concentrations of VLDL2, IDL
and LDL were two- to threefold higher in patients com-
pared to controls (Table 4). VLDL1 concentrations also
showed a trend towards higher levels. In contrast, HDL
concentrations were similar and lipid and protein compo-
sitions of VLDL1, VLDL2, IDL and LDL were the same in
patients and in controls (data not shown). Patients and
controls were on standard diets with a protein content
estimated from questionnaires of 15 to 25% of the daily
calorie intake. Seven-day weighed food intake protocols
from a subset of individuals (3 patients and 4 controls)
indicated no differences in protein consumption, which was
in the range of 0.7 to 1.6 g/kg/day.
Seven males and two females served as a control group.
Subjects were normolipidemic with total cholesterol levels
of 155 to 232 mg/dl and triglyceride levels of 40 to 122
mg/dl. Patients and controls were of similar body frame
(body mass index 26 6 4 vs. 23 6 4 kg/m2). On average,
patients were nine years older than controls (44 6 15 vs.
35 6 8 years; Tables 2 and 3).
The typical curve patterns for tracer/tracee ratios as
measured in the VLDL1, VLDL2, IDL and LDL fractions
are shown in Figure 1 for two patients and for two control
subjects who received the tracer amino acid either as a
bolus injection or as an infusion. Multicompartmental
kinetic analysis was employed to determine rates of apoli-
poprotein B production, transfer and catabolism for each
of the four lipoproteins under investigation. Calculations
were based on observed tracer/tracee ratios, measured apo
B pools and the metabolic model shown in Figure 2A.
Individual values for each study participant are given in
Table 4. The rate of direct VLDL1 catabolism and of
VLDL1 to VLDL2 transfer were lower in patients than in
controls, in line with the nonsignificant increase in plasma
VLDL1 observed in these patients. A more than threefold
increase of VLDL2 concentrations (13.2 vs. 3.9 mg/dl, P 5
0.001) was mainly due to a delayed transfer of VLDL2 to
IDL (2.65 vs. 4.95 pools/day, P 5 0.007). The absolute
amount of VLDL2 transferred into IDL, calculated as the
product of the fractional transfer rate and the size of the
VLDL2 pool, was higher in patients than in controls (14.2
vs. 9.5 mg/kg/day, P 5 0.013). This is because the substan-
tially increased VLDL2 pool more than compensated for
the significant reduction of the VLDL2 transfer rate. The
higher influx from VLDL2 in combination with a dimin-
ished rate of IDL to LDL transfer (0.99 vs. 1.79 pools/day,
P 5 0.002) gave rise to a twofold increase of the IDL
concentration (28.0 vs. 12.2 mg/dl, P 5 0.001). Most of the
IDL mass (71 6 16% of the total) was attributed to a
compartment (comp. 13 in Fig. 2) that does not contribute
to the formation of LDL but is cleared by direct catabolism
of particles. The remainder of IDL represented by com-
partment 12 was further delipidated to become eventually
LDL (comp. 14). In controls the IDL mass was more evenly
distributed between the two IDL compartments (48% and
52%, respectively). The LDL concentration was more than
50% higher in patients than in controls (105.6 vs. 63.9
mg/dl, P 5 0.001) due to a significantly lower LDL frac-
tional catabolic rate (0.29 vs. 0.48 pools/day, P 5 0.034).
The rate of total apolipoprotein B production was higher in
patients than in controls (30.0 vs. 22.0 mg/kg/day), but the
difference failed to reach significance (P 5 0.153). The
distribution of direct apo B secretion into different lipopro-
tein fractions was similar in both groups: on average 60 to
65% of the total apo B production was observed in the
VLDL1 density range, 10 to 15% occurred as a constituent
of VLDL2, and the remaining 20 to 30% of direct apo B
production were distributed between IDL and LDL.
The time courses for albumin tracer/tracee ratios from
two patients with nephrotic syndrome and from two control
subjects are given in Figure 3. Based on multicompartmen-
tal kinetic analysis and the model of albumin metabolism
shown in Figure 2 b. rates of albumin synthesis and
elimination from plasma were calculated as listed in Table
5 and 6. The fractional rate of albumin elimination (FER)
was almost three times higher in patients than the frac-
tional rate of albumin catabolism (FCR) in normal controls
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(median 0.196 vs. 0.067 pools/day, P 5 0.003), which was
due to marked urinary protein losses in nephrosis (Table
1). In nephrotics the fractional catabolic rate (FCR) of
albumin due to endogenous degradation, calculated as the
difference between albumin eliminated from plasma and
renal albumin loss, was very similar to the albumin FCR
measured for controls, indicating that physiological mech-
anisms of albumin degradation were unperturbed in this
group of patients. The absolute amount of albumin catab-
olized per day, however, was decreased by 40% in patients
compared to controls (5.36 vs. 9.12 g/day, P 5 0.010).
Albumin synthesis was determined in the range of 148 to
220 mg/kg/day in nephrotics, which is on average 45%
higher than the values found in normal controls (96 to 152
mg/kg/day, P 5 0.034). This increase in albumin production
was not sufficient to compensate for renal albumin excre-
tion with the result of an almost 50% reduction of the
albumin serum concentration (2.6 6 0.4 vs. 4.9 6 0.4 g/dl,
P 5 0.003). Where the tracer amino acid had been admin-
istered as a primed constant infusion the fractional elimi-
nation rate (FER) of albumin was also determined by an
alternative method whereby a monoexponential function
was fitted to the albumin tracer/tracee curve observed
during the time of infusion. Values for albumin FER
calculated in five subjects either by multicompartmental
modeling or by monoexponential curve fitting were virtu-
ally identical (r 5 0.93).
Correlations between the metabolism of albumin and of
apolipoprotein B containing lipoproteins were examined by
linear regression analysis within the group of nephrotic
patients. Neither plasma albumin concentrations nor rates
of albumin synthesis were correlated to the rate of total
apolipoprotein B production (P 5 0.37 and P 5 0.86,
respectively; Fig. 4). There was also no significant correla-
tion between these parameters and any of the other indi-
vidual production rates of apo B in the VLDL1, VLDL2,
IDL or LDL density range. However, an inverse relation-
ship between the rate of VLDL2 synthesis and the plasma
concentration of albumin (r 5 20.74, P 5 0.034) could be
demonstrated.
Two patients (HS, KD) with nephrotic syndrome and
moderate azotemia were studied in addition to the group of
seven patients with normal excretory renal function. These
subjects showed a relatively low level of proteinuria and
almost normal albumin plasma concentrations. Their
VLDL concentrations were markedly increased but their
LDL levels were in the near normal range. Kinetic analysis
of their apo B metabolism revealed high rates of VLDL1-
and VLDL2-apo B production and low rates of VLDL1 and
VLDL2 transfer. Otherwise, their albumin and apolipopro-
tein B metabolism was similar to that observed in the group
of seven other patients. The lack of correlation between
rates of albumin and apo B synthesis mentioned above was
independent of whether or not the two patients were
included in the correlation studies.
DISCUSSION
Reduced plasma albumin concentrations and increased
levels of LDL and other apo B-containing lipoproteins are
typical findings in patients with the nephrotic syndrome.
The present study was designed to investigate to what
extent urinary protein loss and consecutive changes in
albumin metabolism contribute to the abnormalities in
apolipoprotein B metabolism observed in nephrosis. To
this end we studied the metabolism of apo B-containing
lipoproteins and of albumin in nine nephrotic patients
using a novel approach based on stable isotope labeled
amino acid tracer kinetics and simultaneous multicompart-
mental model analysis. Since the tracer is incorporated into
both newly synthesized apo B and albumin alike, their
metabolism can be studied under identical circumstances in
the same individual at the same time. This avoids some of
Fig. 3. Time courses of leucine tracer/tracee ratios from albumin in two
patients with nephrotic syndrome (f KF in A and f JO in B) and in two
normal control subjects (M JH in A and M CS in B). Tracer was given as
a bolus in JH and KF (A) and as a primed constant infusion in CS and JO
(B). Observed data are given as symbols, calculated values are represented
by continuous solid lines.
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the ambiguities of earlier work addressing the interconnec-
tions between albumin and lipoprotein metabolism in ne-
phrotic patients. Seven out of nine patients participating in
this study were similar in that they were markedly hy-
poalbuminemic and hypercholesterolemic but showed no
signs of chronic renal failure, which in itself may cause
secondary hyperlipidemia [2]. These patients were com-
pared to nine normolipidemic subjects in the control group.
Additionally, two nephrotic subjects (HS and KD) with
concomitant mild to moderate renal failure and hypertri-
glyceridemia were examined. Results from their metabolic
studies were of particular interest in comparison to previ-
ously published work where often nephrotic patients with
some degree of renal failure have been investigated [8–10].
Increased concentrations of VLDL2, IDL and LDL in
the patient group were the result of three metabolic
abnormalities that were: (a) significantly reduced rates of
VLDL2 to IDL and of IDL to LDL transfer, (b) a signifi-
cantly lower LDL-FCR, and (c) a trend for an increased
rate of total apolipoprotein B production. In a previous
study we investigated the metabolism of apo B containing
lipoproteins in eight nephrotic patients with concomitant
mild to moderate renal failure using a dual radioiodinated
VLDL tracer technique [8]. Similar deviations from normal
apo B metabolism were observed: (a) the rates of transfer
from VLDL1 to VLDL2 and from VLDL2 to IDL were
significantly reduced, (b) LDL-FCRs were in most patients
lower than in controls, and (c) apo B production in
particular in the VLDL2 density range was increased.
Delipidation of lipoproteins from triglyceride rich
VLDL1 down to LDL is mediated by two lipolytic enzymes,
lipoprotein lipase and hepatic lipase, which have partially
overlapping substrate specificities [34, 35]. Catalytic activi-
ties of both enzymes have been studied in human and in
experimental nephrosis and were found to be significantly
reduced [13, 36, 37], although these observations were not
consistently confirmed by others [38, 39]. Possible mecha-
nisms for impaired lipolytic activity are the urinary loss of a
low molecular weight glycoaminoglycan, which has been
shown to act as an activator of lipoprotein lipase in vivo and
in vitro [16], or a relative depletion of apo CII, an obligatory
activator of lipoprotein lipase, which in nephrotic patients
was found to be reduced relative to the increased number
of VLDL particles [36]. Proteinuria in our patients was
positively correlated with the concentration of VLDL2 (r 5
Fig. 4. Lack of association of the rate of albumin synthesis and the rate
of total apolipoprotein B production in nine patients with nephrotic
syndrome (M) and in six control subjects (f).
Table 5. Albumin metabolic parameters in patients with nephrotic syndrome
Name
Alb. synthesis
mg/kg/day
Alb. pool
g
Alb. FER
pools/day
abs. Alb. elim. Albuminuria abs. Alb. catab
Alb. FCR
pools/dayg/day
WM 219 98.4 0.200 19.67 14.0 5.67 0.058
KF 218 102.5 0.217 22.24 14.0 8.24 0.080
JO 169 77.9 0.152 11.84 10.1 1.74 0.022
HA 220 82.4 0.196 16.15 9.6 6.55 0.080
MC 149 80.7 0.140 11.30 9.3 2.00 0.024
EA 148 42.2 0.226 9.53 — — —
ED 173 55.8 0.173 9.66 4.6 5.06 0.091
Median 173 80.7 0.196 11.84 9.9 5.37 0.069
Range 148–220 42.2–102.5 0.14–0.23 9.5–22.2 4.6–14.0 1.7–8.2 0.02–0.09
HS 185 138.90 0.120 16.67 5.4 11.27 0.081
KD 231 175.83 0.122 21.45 3.9 17.55 0.100
P value
Neph. vs. Cont. 0.010 0.007 0.003 0.010
Abbreviations are: Alb., albumin; FER, rate of elimination of albumin from plasma; FCR, fractional catabolism rate; catab, catabolism; abs., absolute.
Table 6. Albumin metabolic parameters in normal controls
Name
Alb. synthesis
mg/kg/day
Alb. pool
g
Alb. FCR
pools/day
abs. Alb. catab.
g/day
CE 153 115.1 0.081 9.33
RB 118 187.0 0.067 12.53
CS 130 145.2 0.067 9.73
WS 96 159.2 0.050 7.96
JD 149 97.9 0.091 8.91
GH 124 117.4 0.060 7.04
Median 127 131.3 0.067 9.12
Range 96–153 97.9–187.0 0.05–0.09 7.04–12.53
Abbreviations are as in Table 5.
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1 0.76, P 5 0.077) and negatively with the transfer rate
from VLDL2 to IDL (r 5 20.82, P 5 0.047), which is in
support of the concept that the urinary loss of an activator
of lipolytic enzymes is of importance. Since in in vitro
experiments VLDL isolated from nephrotic subjects is
insufficiently hydrolyzed when incubated with normal li-
poprotein lipase [40], it is assumed that both substrate and
enzyme abnormalities play a role in delayed lipoprotein
delipidation in nephrotic syndrome. In the present study
VLDL1 delipidation was only marginally decreased but the
delipidation of VLDL2 and IDL was significantly reduced.
It is likely, therefore, that hepatic lipase with its preferen-
tial affinity for VLDL2 and IDL was primarily affected in
this group of patients. However, patients HSC and KDH,
who were more akin to the subjects from our previous
study, showed rather low rates of VLDL1 delipidation,
which is in accordance with the significant reduction in this
delipidation step reported in this study [8].
The catabolism of LDL has been studied in patients with
nephrotic syndrome by several groups using different study
protocols. LDL turnovers with an exogenously radioiodi-
nated LDL tracer [6, 9, 10], the dual radioiodinated VLDL
tracer protocol [8] and endogenous labeling with stable
isotopes [12] as used in the present study have all been
employed. In four studies of nephrotic patients with hyper-
cholesterolemia or mixed hyperlipidemia the LDL-FCR
was found to be in the lower range of normal [6, 8, 10] or
significantly reduced [9]. This is in accordance with the
present study where the LDL-FCR in patients was on
average 35% lower than in controls. We have shown
previously that the delay in LDL catabolism observed in
nephrotic subjects was mainly due to a reduced clearance
via the LDL receptor pathway [9]. Down-regulation of
hepatic LDL receptors might be caused by increased
hepatic cholesterogenesis that was observed at least in
experimental nephrosis in rats as a result of increased
retention of mevalonate [15]. However, since mevalonate
levels were not determined in the present study this mech-
anism remains speculative. Alternatively, LDL from hyper-
triglyceridemic subjects has been shown in vitro to bind less
avidly to LDL receptors, which also explains why LDL in
nephrotic subjects is catabolized more slowly. Indeed, in a
recent study of normolipidemic to moderately hyperlipid-
emic subjects we were able to demonstrate that the LDL-
FCR in the upper triglyceride tertile (.140 mg/dl) was 50%
lower than in the lower tertile (,80 mg/dl). It should be
noted that in two studies examining nephrotic patients with
excessive hypertriglyceridemia (.500 mg/dl) the LDL-FCR
was actually found to be higher than in normolipidemic
controls [10, 12]. This is in line with similar findings in
comparable states of extreme hypertriglyceridemia due to
other metabolic disorders [36] and reflects an increased
LDL degradation by LDL receptor-independent mecha-
nisms [41].
A trend towards an increased production of apolipopro-
tein B was the third component, after impaired lipoprotein
delipidation and decreased LDL catabolism, which contrib-
uted to the hyperlipidemia observed in the patient group.
This difference, although statistically not significant, is in
line with similar findings reported from other studies in
humans [8–12] and in experimental animals [13, 14]. In
nephrotic syndrome both increased triglyceride production
and increased cholesterogenesis have been observed in
animal studies [15, 42] and in humans [43]. Evidence from
in vitro experiments with hepatoma cell lines suggests that
intracellular availability of lipids is an important regulator
of hepatic VLDL secretion [44]. In vivo studies in normo-
lipidemic and hyperlipidemic subjects support the view that
increased biosynthesis of triglycerides [45] and of choles-
terol [46] are associated with increased production rates for
large triglyceride rich VLDL1 or smaller cholesteryl ester
rich VLDL2. It is likely that both mechanisms contribute to
the overproduction of apo B-containing lipoproteins ob-
served in nephrotic patients.
To find out whether this increase in apo B production
was linked to changes in albumin metabolism, in particular
to an increased rate of albumin synthesis, we took advan-
tage of the possibility offered by a stable isotope labeled
amino acid tracer study to simultaneously examine the
synthesis and degradation of more than one protein [26].
The fractional rate of albumin elimination from plasma was
almost three times increased and showed the expected
positive correlation with the rate of urinary protein loss
(r 5 10.71, P 5 0.03). Albumin synthesis was significantly
higher in patients compared to controls, a finding con-
firmed by earlier studies in animals and in humans [47, 48].
In a recent study by Ballmer and Weber, albumin synthesis
was determined in seven nephrotic patients and eight
controls by use of stable isotope labeled leucine and the
“flooding dose protocol” [22]. Their absolute values were
only slightly higher (214 6 48 and 144 6 10 mg/kg/day in
patients and controls, respectively) and the relative in-
crease of 48% in patients was almost identical to our study.
In a study by Kaysen et al rates of albumin synthesis were
measured using radioiodinated albumin and a pharmaco-
kinetic method [23]. In 13 nephrotic patients with marked
proteinuria, the rate of albumin production was either
within the normal range or significantly increased depend-
ing on the protein content of the diet. Quantitative dietary
records were taken only in three of our patients, but it
should be noted that the protein content of their diets (0.7
to 1.6 g/kg/day) varied within the same range as in the study
above.
In nephrotic syndrome, the causal relationships between
disturbances in the metabolism of albumin on the one hand
and apo B-containing lipoproteins on the other hand are
not clear. One hypothesis suggested by early workers in the
field is that a general increase in hepatic protein synthesis
is responsible for both overproduction of lipoproteins and
albumin [21]. Linear regression analysis of the production
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rates for albumin and apolipoprotein B that were simulta-
neously determined in this study gave no evidence of a
positive correlation. This negative result is supported by the
absence of a correlation between albumin synthesis and
serum cholesterol concentrations reported by Kaysen et al
in the study mentioned above [23]. In contrast to our study,
a positive correlation was reported between albumin syn-
thesis and triglyceride concentrations, but this was much
weaker than the positive association with the rate of renal
albumin clearance. A similar association between the
VLDL2 concentration and the rate of proteinuria observed
in our patient group has been mentioned before.
A second mechanism proposed for the increased hepatic
production of apo B-containing lipoproteins in nephrotic
subjects is related to reduced albumin concentrations in
plasma rather than the increase in hepatic albumin synthe-
sis per se. The inverse correlation between albumin concen-
trations and the rate of VLDL2 production observed in this
study is compatible with this concept. Hypoalbuminemia is
associated with a reduction in the plasma oncotic pressure,
and it has been suggested that this rather than a direct
effect of albumin may result in increased hepatic protein
production [18, 49]. Early studies have shown that the
hyperlipidemia in nephrotic patients can be reversed by
administration of either albumin or dextran infusions [49].
More recently, in vitro studies with Hep G2 cells demon-
strated a dose-dependent inhibitory effect of albumin on
cellular apo B production [19, 20] and a suppression of
intracellular apo B degradation at low albumin levels [50].
It has also been shown in a rat hepatoma cell line that apo
B and albumin gene transcription are regulated by the
oncotic pressure in the culture medium [18]. The inverse
association between VLDL2 synthesis and albumin concen-
tration together with the significant increase in VLDL2
production reported in our previous study [8] point at a
mechanism that is either driven by a reduction in the
plasma oncotic pressure or, as mentioned before, by an
increase of cholesterol biosynthesis [42, 43]. Higher rates of
triglyceride production, on the other hand, would primarily
enhance the hepatic secretion of triglyceride rich large
VLDL1 rather than of cholesteryl ester rich smaller
VLDL2. However, in the absence of direct measurements
the correlations within a small group of patients are too
weak to support further speculation.
In conclusion, the present study shows that the predom-
inant defects in apolipoprotein B metabolism in nephrotic
patients are reduced rates of lipoprotein delipidation and
catabolism combined with a less consistent increase in apo
B production. The turnover of albumin is increased due to
a threefold increase in the fractional rate of albumin
elimination and a significant increase in albumin synthesis.
Associations between metabolic parameters for apoli-
poprotein B and albumin are weak and in particular they
were undetectable at the level of hepatic protein synthesis.
Key features in nephrotic syndrome, impaired albumin and
lipoprotein metabolism, seem to develop in parallel, probably
precipitated through proteinuria, and direct interactions be-
tween the metabolism of both are of minor importance.
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APPENDIX I
Kinetics of free leucine and leucine prepared from apolipoprotein B from patients with nephrotic syndrome. Calculated values are given for k(i,j) and
M(i), figures in italics denote fractional standard deviations.
WM KF JO HA MC
k(0,1)a 2.950 0.019 1.203 0.029 4.085 0.134 0.621 0.015 2.034 0.046
k(3,1) 5.829 0.027 1.823 0.039 5.858 0.176 2.745 0.011 2.576 0.039
k(1,3) 0.417 0.052 0.107 0.090 0.609 0.083 0.070 0.027 0.189 0.032
k(4,3) 0.416 0.027 0.257 0.063 0.568 0.038 0.162 0.030 0.262 0.028
K(3,4) 0.021 0.030 0.033 0.038 0.025 0.053 0.036 0.015 0.024 0.040
k(2,1) 6.923 0.050 3.213 0.081 6.803 0.149 2.888 0.019 9.044 0.105
k(5,2) 0.068 0.017 0.028 0.021 0.039 0.130 0.027 0.009 0.034 0.036
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WM KF JO HA MC
P(1)b 0.942 0.008 0.928 0.008 0.847 0.009 0.509 0.006 0.965 0.026
d(9,5)c 0.225 0.021 0.055 0.239 0.081 0.244 0.054 0.073 0.070 0.089
d(12,5) 0.024 0.086 0.098 0.029 0.039 0.165 0.142 0.016 0.053 0.028
d(14,5) 0.000 — 0.050 0.046 0.220 0.022 0.260 0.010 0.061 0.030
k(7,6) 1.140 0.071 10.00 .0.50 2.923 0.316 3.389 0.063 9.273 0.270
k(0,7) 0.060 0.074 0.161 0.298 0.073 0.266 0.100 .0.50 0.617 0.034
k(8,6) 0.000 — 0.346 0.053 0.057 0.272 0.010 .0.50 0.389 0.251
k(0,8) 0.000 — 0.092 0.042 0.025 0.063 1.000 .0.50 0.120 0.053
k(9,7) 0.111 0.030 1.103 0.025 0.641 0.039 1.387 0.020 0.404 0.017
k(0,10) 0.028 0.073 0.038 0.032 0.000 — 0.000 — 0.000 —
k(12,10) 0.053 0.021 0.076 0.018 0.077 0.029 0.107 0.004 0.080 0.016
k(13,10) 0.031 0.039 0.028 0.060 0.052 0.046 0.007 0.039 0.013 0.104
k(14,12) 0.231 0.047 0.112 0.037 0.084 0.049 0.157 0.014 0.069 0.023
k(0,14) 0.012 0.015 0.012 0.011 0.008 0.016 0.020 0.004 0.013 0.012
k(14,15) 0.002 0.214 0.000 — 0.000 — 0.000 — 0.000 —
Q(1)d 179 569 134 413 345
Q(2) 177 565 133 409 343
Q(3) 2499 9667 1291 16310 4701
Q(4) 49238 74601 29796 74096 50602
U(1)e 540 700 554 268 712
Q(6) 7.9 1.2 1.2 1.8 1.0
Q(7) 52.9 9.6 4.7 4.0 9.0
Q(8) 8.7 4.6 2.6 0.0 3.2
M(VLDL-1)f 69.5 70 15.4 15 8.5 8 5.8 6 13.2 13
Q(9) 7.5 1.1 1.2 1.8 0.5
Q(10) 77.0 78.2 26.3 53.9 46.5
Q(11) 8.3 4.2 2.6 0.0 1.5
M(VLDL-2) 92.8 93 83.5 84 30.1 30 55.7 57 48.5 48
Q(12) 17.0 49.9 26.3 46.7 62.3
Q(13) 56.3 70.1 68.5 225.4 41.9
M(IDL) 73.3 73 120.0 120 94.8 95 272.1 271 104.2 106
M(LDL)5Q(14) 322.4 322 522.4 522 408.2 408 513.7 517 374.6 375
Q(15) 129.0 208.9 163.3 205.5 149.8
EA ED HS KD
k(0,1)a 1.890 0.019 1.000 .0.50 2.077 0.070 1.222 0.034
k(3,1) 5.549 0.028 3.639 0.011 3.880 0.071 1.377 0.057
k(1,3) 0.271 0.056 0.022 0.017 0.047 0.081 0.303 .0.50
k(4,3) 0.418 0.030 0.029 0.024 0.070 0.074 0.574 0.101
k(3,4) 0.051 0.026 0.003 0.040 0.019 0.044 0.041 0.091
k(2,1) 3.403 0.019 2.302 0.016 2.500 .0.50 2.295 0.088
k(5,2) 0.043 0.018 0.024 0.009 0.059 0.062 0.026 0.024
P(I)b 0.850 0.008 0.603 0.008 0.929 0.008 0.900 0.010
d(9,5)c 0.273 0.009 0.228 0.014 0.230 0.024 0.193 0.053
d(12,5) 0.084 0.029 0.098 0.011 0.044 0.045 0.080 0.053
d(14,5) 0.253 0.016 0.040 0.023 0.046 0.049 0.004 .0.50
k(7,6) 1.912 0.059 0.225 0.009 10.00 .0.50 0.263 0.101
k(0,7) 0.000 — 0.001 .0.50 0.005 .0.50 0.000 —
k(8,6) 0.014 0.315 0.101 0.018 0.000 — 0.155 0.110
k(0,8) 0.142 0.271 0.813 0.088 0.000 — 0.500 .0.50
k(9,7) 2.256 0.063 2.952 0.103 0.122 0.042 0.469 0.163
k(0,10) 0.000 — 0.000 — 0.052 0.050 0.000 —
k(12,10) 0.261 0.008 0.162 0.015 0.055 0.026 0.043 0.035
k(13,10) 0.069 0.014 0.150 0.020 0.020 0.074 0.054 0.042
k(14,12) 0.575 0.017 0.134 0.016 0.134 0.055 0.110 0.049
k(0,14) 0.017 0.006 0.008 0.005 0.015 0.014 0.011 0.018
k(14,15) 0.000 — 0.000 — 0.000 — 0.000 —
Q(1)d 257 272 206 685
Q(2) 254 269 201 677
Q(3) 5274 45888 16875 3108
Q(4) 43350 393074 61785 43841
U(1)e 497 279 439 854
Q(6) 2.2 12.6 0.8 30.1
Q(7) 1.9 1.0 63.3 16.9
Q(8) 0.2 1.6 0.8 9.3
M(VLDL-1)f 4.3 4 15.2 16 66.5 67 56.3 58
Q(9) 3.7 13.2 1.0 27.0
Q(10) 21.5 9.5 81.7 72.9
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APPENDIX II
Kinetics of free leucine and leucine prepared from apolipoprotein B from normolipidemic controls. Calculated values are given for k(i,j) and M(i),
figures in italics denote fractional standard deviations.
BG CE MM BJ RB
k(0,1)a 2.227 0.030 2.068 0.016 2.402 0.016 1.267 0.006 1.491 0.004
k(3,1) 2.780 0.024 4.845 0.010 1.654 0.057 1.477 0.007 2.611 0.005
k(1,3) 0.047 0.034 0.770 0.017 0.129 0.046 0.235 — 0.344 0.004
k(4,3) 0.024 0.041 0.592 0.012 2.500 — 0.172 — 0.510 0.003
k(3,4) 0.009 0.012 0.021 0.026 0.250 — 0.017 — 0.051 0.003
k(2,1) 3.131 0.035 2.500 — 2.500 — 2.500 — 2.500 —
k(5,2) 0.026 0.012 0.018 0.014 0.016 0.016 0.014 0.003 0.031 0.004
P(1)b 0.817 0.005 0.844 0.004 0.673 0.005 0.532 0.001 0.556 0.001
d(9,5)c 0.147 0.054 0.045 0.185 0.100 .0.50 0.020 .0.50 0.061 0.026
d(12,5) 0.035 0.011 0.059 0.028 0.379 0.009 0.038 0.012 0.142 0.005
d(14,5) 0.136 0.025 0.022 0.049 0.210 0.009 0.172 0.006 0.055 0.005
k(7,6) 5.000 .0.50 2.262 0.009 10.00 .0.50 0.513 0.005 10.00 —
k(0,7) 0.000 — 14.23 0.270 0.635 .0.50 1.464 0.012 0.640 0.008
k(8,6) 0.000 — 0.100 .0.50 0.413 0.054 0.002 0.009 0.401 0.063
k(0,8) 0.000 — 0.070 0.024 0.099 0.042 0.001 0.008 0.286 0.035
k(9,7) 0.667 0.015 9.603 0.274 0.839 0.021 0.626 0.007 0.590 0.009
k(0,10) 0.030 0.072 0.000 — 0.000 — 0.000 — 0.000 —
k(12,10) 0.376 0.009 0.181 0.010 0.131 0.119 0.600 .0.50 0.199 0.003
k(13,10) 0.019 0.045 0.074 0.024 0.004 0.236 0.000 — 0.070 0.008
k(14,12) 0.125 0.020 0.366 0.024 0.172 0.008 0.058 0.002 0.219 0.004
k(0,14) 0.020 0.013 0.012 0.008 0.026 0.006 0.018 0.002 0.027 0.002
k(14,15) 0.008 0.105 0.000 — 0.000 — 0.003 0.021 0.007 0.018
Q(1)d 222 375 470 588 607
Q(2) 220 373 467 585 600
Q(3) 13055 2361 6038 3695 4609
Q(4) 36314 66910 60377 36946 46087
U(1)e 500 783 1135 753 924
Q(6) 0.8 2.5 0.2 1.9 1.3
Q(7) 5.9 0.2 1.5 3.0 10.6
Q(8) 0.8 3.6 1.0 0.8 1.8
M(VLDL-1)f
Q(9) 1.0 1.1 0.2 3.9 0.7
Q(10) 11.5 9.8 14.2 3.4 27.5
Q(11) 1.0 1.6 0.9 8.6 0.0
M(VLDL-2)
Q(12) 29.3 6.0 27.2 39.7 36.9
Q(13) 11.5 24.9 37.5 0.0 61.4
M(IDL)
M(LDL)5Q(14) 223.5 188.9 237.8 209.7 334.0
Q(15) 89.4 75.6 95.1 83.9 133.6
APPENDIX I (CONTINUED)
EA ED HS KD
Q(11) 0.4 1.6 1.0 8.3
M(VLDL-2) 25.6 25 24.3 25 83.7 84 108.2 108
Q(12) 11.3 16.3 26.8 41.0
Q(13) 84.9 48.8 40.5 81.2
M(IDL) 96.2 97 65.1 66 67.3 67 122.2 122
M(LDL)5Q(14) 538.0 540 276.6 276 277.2 270 405.6 406
Q(15) 215.2 110.6 110.9 162.4
a k(i,j) describe the transfer of leucine from compartment j to i as fraction of pool j per hour. Fractional standard deviations (FSD) are given in
parenthesis. k(i,j) values are transformed into kinetic transfer rates of apolipoprotein B from compartment j to i per day by multiplication with a constant
factor (that is times 24 hours divided through 0.1212, the fractional leucine content of apo B). For model constraints see Methods.
b P(1) is a dilutional factor calculated to determine the apo B precursor pool enrichment in compartment 5. It is mathematically equivalent to U(5).
For details see Methods and [24].
c d(i,5) describe the distribution of material leaving the delay compartment (compartment 5, Fig. 2) and entering the apo B compartments 6, 9, 12
and 14. d(6,5) 1 d(9,5) 1 d(12,5) 1 d(14,5) 5 1.00.
d Q(i) is the leucine mass (mg) in compartment i. M(i) can be transformed into corresponding apo B masses by division through 0.1212 (i.e. the
fractional leucine content of apo B).
e U(1) is the calculated tracee (i.e. native leucine) input into compartment 1.
f For M(VLDL-1), M(VLDL-2), M(IDL), and M(LDL) calculated and directly measured masses are given in italics.
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CS WS JD GH
k(0,1)a 0.730 0.038 1.362 0.012 1.111 0.010 2.008 0.008
k(3,1) 1.573 0.023 1.455 0.010 1.618 0.007 2.175 0.010
k(1,3) 0.016 0.056 0.092 0.022 0.093 0.020 0.187 0.015
k(4,3) 0.030 0.013 0.162 0.013 0.173 0.016 0.286 0.010
k(3,4) 0.019 0.014 0.016 0.013 0.017 0.016 0.029 0.010
k(2,1) 13.16 0.093 2.543 0.022 2.389 0.012 2.610 0.013
k(5,2) 0.014 0.016 0.017 0.012 0.015 0.005 0.030 0.012
P(1)b 0.752 0.010 0.667 0.002 0.587 0.002 0.676 0.005
d(9,5)c 0.153 0.042 0.169 0.019 0.104 0.033 0.150 .0.50
d(12,5) 0.107 0.025 0.025 0.072 0.108 0.014 0.191 0.015
d(14,5) 0.157 0.020 0.000 — 0.189 0.007 0.007 0.036
k(7,6) 1.812 0.074 10.00 .0.50 7.000 .0.50 25.05 0.075
k(0,7) 0.000 — 0.660 0.031 0.500 .0.50 1.000 .0.50
k(8,6) 0.017 0.013 0.007 .0.50 3.537 0.013 0.000 —
k(0,8) 0.020 0.013 0.028 .0.50 1.043 0.010 0.000 —
k(9,7) 0.636 0.020 0.497 0.016 5.000 .0.50 1.200 .0.50
k(0,10) 0.160 0.022 0.000 — 0.000 — 0.205 0.017
k(12,10) 0.256 0.023 0.246 0.006 0.235 0.004 0.361 0.010
k(13,10) 0.014 0.050 0.096 0.012 0.004 0.082 0.035 0.020
k(14,12) 0.221 0.028 0.454 0.011 0.109 0.006 0.324 0.015
k(0,14) 0.024 0.014 0.011 0.003 0.021 0.003 0.016 0.006
k(14,15) 0.004 0.014 0.000 — 0.000 — 0.000 —
Q(1)d 567 520 470 279
Q(2) 567 518 467 276
Q(3) 54504 8224 8152 3248
Q(4) 86400 82236 81524 32479
U(1)e 422 718 529 568
Q(6) 2.6 0.7 0.4 0.2
Q(7) 7.4 6.2 0.5 2.4
Q(8) 2.2 0.2 1.3 0.2
M(VLDL-1)f 12.2 12 7.1 7 2.2 3 2.8 3
Q(9) 3.3 0.5 0.3 0.2
Q(10) 13.7 13.4 9.0 6.9
Q(11) 2.7 0.1 1.0 0.2
M(VLDL-2) 19.7 20 14.0 14 10.3 8 7.3 8
Q(12) 11.5 7.8 26.4 7.7
Q(13) 13.7 45.8 9.0 25.8
M(IDL) 25.2 26 53.6 55 35.4 37 33.5 35
M(LDL)5Q(14) 162.0 162 312.3 314 200.1 206 158.3 157
Q(15) 64.8 124.9 80.1 63.3
For footnotes see Appendix I.
APPENDIX III
Kinetics of free leucine and leucine prepared from albumin from patients with nephrotic syndrome. Calculated values are given for k(i,j) and M(i),
figures in italics denote fractional standard deviations.
WM KF JO HA MC
k(0,1)a 2.5944 0.016 1.1519 0.041 3.8419 0.016 0.5000 .0.50 0.5822 0.023
k(3,1) 14.899 0.062 1.4673 0.039 5.2488 0.060 2.8305 0.012 2.5057 0.017
k(1,3) 2.6566 0.092 0.0583 0.091 0.3254 0.241 0.0274 0.042 0.0640 0.061
k(4,3) 0.5576 0.050 0.1185 0.097 0.4105 0.111 0.0365 0.086 0.1776 0.056
k(3,4) 0.0122 0.041 0.0267 0.055 0.0169 0.104 0.0101 0.084 0.0254 0.027
k(2,1) 1.1074 .0.50 2.3958 0.115 2.5000 .0.50 0.7694 0.040 2.5000 .0.50
k(5,2) 1.0888 0.033 0.2793 0.034 0.4245 0.027 0.2699 0.031 0.1245 0.020
P(1)b 0.942 0.928 0.847 0.509 0.965
k(7,6) 0.0055 0.099 0.0200 .0.50 0.0001 0.100 0.0193 0.118 0.0071 0.027
k(6,7) 0.0017 0.213 0.0223 0.096 0.0001 0.100 0.0108 0.166 0.0003 0.316
k(0,6) 0.0083 0.015 0.0091 0.024 0.0063 0.024 0.0085 0.016 0.0059 0.017
Q(1)c 179 446 145 421 460
Q(2) 90 399 139 312 454
Q(3) 1003 11219 2338 43489 18017
Q(4) 46002 49890 56769 157313 126154
U(1)d 562 12100 625 616 85 325
M(Alb.)5Q(6) 11802 12296 12880 9350 9408 9889 10100 9687 9740
Q(7) 38050 11048 9350 17680 226578
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Kinetics of free leucine and leucine prepared from albumin from normal controls. Calculated values are given for k(i,j) and M(i), figures in italics denote
fractional standard deviations.
CE RB CS WS JD GH
k(0,1)a 0.6386 0.154 0.6677 0.022 0.3000 .0.50 1.7625 0.011 1.6331 0.016 2.2635 0.008
k(3,1) 4.7563 0.031 3.0626 0.010 0.9465 0.039 1.3797 0.045 2.1374 0.031 1.0911 0.025
k(1,3) 0.1840 0.071 0.0937 0.038 0.0066 0.061 0.1775 0.124 0.1399 0.062 0.0857 0.059
k(4,3) 0.3796 0.037 0.2721 0.031 0.0090 0.105 0.1471 0.082 0.2217 0.038 0.1101 0.071
k(3,4) 0.0155 0.048 0.0424 0.022 0.0027 0.109 0.0174 0.052 0.0158 0.041 0.0296 0.040
k(2,1) 4.7900 0.082 2.1585 0.024 0.4644 0.084 6.5994 0.188 4.2957 0.097 2.5000 ,0.50
k(5,2) 0.1931 0.034 0.1007 0.010 0.0551 0.048 0.0847 0.034 0.1530 0.037 0.1268 0.036
P(1)b 0.844 0.556 0.752 0.667 0.587 0.676
k(7,6) 0.0100 0.139 0.0125 0.026 0.0100 0.100 0.0047 0.156 0.0128 0.126 0.0170 0.118
k(6,7) 0.0035 0.226 0.0011 0.118 0.0109 0.092 0.0027 0.362 0.0109 0.139 0.0114 0.128
k(0,6) 0.0034 0.022 0.0028 0.008 0.0028 0.032 0.0021 0.021 0.0038 0.025 0.0025 0.024
Q(1)c 250 655 1005 475 303 291
Q(2) 240 625 899 469 293 277
Q(3) 6462 21403 143736 3692 4629 3706
Q(4) 15705 137272 483350 31263 65048 13800
U(1)d 206 500 351 877 540 694
M(A1b.)5Q(6) 13815 14100 22440 23010 17826 12150 19101 19300 11753 12150 14084 14300
Q(7) 39207 251780 16408 32722 13854 20935
APPENDIX III (CONTINUED)
EA ED HS KD
k(0,1)a 0.5000 .0.50 0.2444 .0.50 0.8030 0.076 0.7172 0.005
k(3,1) 4.6795 0.019 3.3297 0.003 3.2329 0.031 2.5130 0.010
k(1,3) 0.0853 0.033 0.0089 0.007 0.0851 0.113 0.2389 0.010
k(4,3) 0.3507 0.020 0.0180 0.008 0.1303 0.090 0.5789 0.024
k(3,4) 0.0314 0.025 0.0037 0.008 0.0158 0.071 0.0579 0.030
k(2,1) 2.8261 0.029 0.9264 0.013 2.5000 .0.50 0.3250 .0.50
k(5,2) 0.4101 0.028 0.2215 0.007 0.2869 0.032 0.2844 0.023
P(1)b 0.850 0.603 0.929 0.900
k(7,6) 0.0001 0.100 0.0113 0.032 0.0058 0.147 0.0434 0.014
k(6,7) 0.0001 0.100 0.0132 0.032 0.0034 0.361 0.0062 0.015
k(0,6) 0.0094 0.012 0.0072 0.004 0.0050 0.019 0.0051 0.008
Q(1)c 133 270 300 705
Q(2) 116 218 292 376
Q(3) 7291 101629 11402 7417
Q(4) 81510 501642 94195 74166
U(1)d 114 114 325 613
M(A1b.)5Q(6) 5062 5170 6701 6800 16669 16900 21099 20850
Q(7) 5072 5720 28581 147243
a k(i,j) values are transformed into kinetic transfer rates of albumin from compartment j to i per day by multiplication with a constant factor (that
is times 24 hours divided through 0.1200, the fractional leucine content of albumin).
b P(1) is the dilutional factor which defines the hepatic precursor pool enrichment in compartment 5. It was determined in the apo B turnover studies
documented in Appendix I. For details see Methods.
c Q(i) is the leucine mass (mg) in compartment i. Q(6) can be transformed into corresponding albumin pools by division through 0.1200 (i.e. the
fractional leucine content of albumin). Measured albumin pools are given in italics.
d U(1) is the calculated tracee (i.e. native leucine) input into compartment 1.
APPENDIX V
Abbreviations used in this article are apo B, apolipoprotein B; FCR, fractional catabolism rate; FER, fractional
elimination rate; FSD, fractional standard deviation; GC-MS, gas chromatography mass spectrometry; HDL, high density
lipoprotein; IDL, intermediate density lipoprotein; VLDL, very low density lipoprotein; LDL, low density lipoprotein.
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